Monitoring parameters typically assessed in trials include: Body weight and BMI measured at each visit to track progress Blood glucose and HbA1c particularly important for participants with type 2 diabetes or non-diabetic hyperglycaemia (sometimes called prediabetes) Lipid profile including total cholesterol, LDL, HDL, and triglycerides Liver function tests given the metabolic effects of glucagon receptor activation Renal function especially relevant if gastrointestinal side effects lead to reduced fluid intake Blood pressure and heart rate cardiovascular parameters are routinely assessed Calcitonin levels some trial protocols include calcitonin measurement given the theoretical thyroid C-cell risk associated with GLP-1 receptor agonists, based on rodent data
CagriSema shows less discontinuation, however increased rates of vomiting and nausea
TRT Nation prescribes tirzepatide, not semaglutide, because the evidence supports it as the superior choice for appropriate candidates
Managing Adverse Effects Retatrutide and tirzepatide, both in the treatment of weight management and type 2 diabetes, have numerous side effects
Henry Meds semaglutide FAQ Sources Innerbody uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles
